Succumbed to BEBOV challenge. a rVSV blend; rVSV-SEBOV-GP plus rVSV-ZEBOV-GP, rVSV Prime-boost; rVSV-SEBOV-GP first then rVSV-ZEBOV-GP 14 days after. −22; day of boost.b Days after BEBOV challenge, D
Groups of 7 mice received three immunizations of 0.1, 1, 2.5, 5 or 10 µg CS/D, adjuvanted with GLA/SE at two week intervals. ELISA end-point titers were measured 2 weeks after the last dose against CS
Note: p-values for comparisons of seroprevalence are based on symmetry test; p-values for comparisons of GMTs between mother and cord are based on paired test of log (NT) The proportion and geometric
Ab Antibody titer. *Nicotine replacement therapy users and subjects with missing titers at months 4 to 6 were excluded; the participants on active treatment were separated into three responder subgrou
